Safety and Efficacy of Rivaroxaban as Extended-Phase Anticoagulation in Patients with Cancer and Venous Thromboembolism: A Preliminary Data Analysis from the Mac Project

Safety and Efficacy of Rivaroxaban as Extended-Phase Anticoagulation in Patients with Cancer and Venous Thromboembolism: A Preliminary Data Analysis from the Mac Project

Extended-phase anticoagulation with direct oral Xa inhibitors (OAXI) is suggested in patients with cancer-associated venous thromboembolism (CAT). We report on patients enrolled in the MAC (Monitoring AntiCoagulants) Project, given rivaroxaban as extended-phase anticoagulation after CAT. The primary...

Full description

Bibliographic Details
Main Authors:	Enrico Bernardi, Giuseppe Camporese, Cristiano Bortoluzzi, Franco Noventa, Davide Ceccato, Chiara Tonello, Stefania Vohong, Elena Campello, Chiara Simion, Egidio Imbalzano, Pierpaolo Di Micco, Elena Callegari, Paolo Simioni
Format:	Article
Language:	English
Published:	MDPI AG 2022-10-01
Series:	Life
Subjects:	cancer-related venous thromboembolism factor Xa inhibitors extended-phase anticoagulation real-life
Online Access:	https://www.mdpi.com/2075-1729/12/11/1725

Similar Items

Safety and Efficacy of Rivaroxaban for Extended-Phase Anticoagulation of Patients with Unprovoked or Recurrent Venous Thromboembolism: Real-Life Data from the MAC Project
by: Cristiano Bortoluzzi, et al.
Published: (2022-10-01)

Variation in Plasma Levels of Apixaban and Rivaroxaban in Clinical Routine Treatment of Venous Thromboembolism
by: Sara Reda, et al.
Published: (2022-05-01)

Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation
by: Francesco Poletto, et al.
Published: (2022-03-01)

Statins during Anticoagulation for Emergency Life-Threatening Venous Thromboembolism: A Review
by: Carmine Siniscalchi, et al.
Published: (2024-07-01)

Safety and Efficacy of Direct Oral Anticoagulants vs Warfarin in Patients With Obesity and Venous Thromboembolism: A Retrospective Analysis
by: Zoe H. Tu, PharmD, et al.
Published: (2024-05-01)

MAC Project—Monitoring Anticoagulant Therapy Observational Study: Rationale and Protocol
by: Giuseppe Camporese, et al.
Published: (2021-01-01)

Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism
by: Dongwon Yoon, et al.
Published: (2023-09-01)

Editorial on the Special Issue “The New Frontier of Venous Thromboembolism”
by: Pierpaolo Di Micco, et al.
Published: (2023-10-01)

Comparison of Intravenous Enoxaparin with Subcutaneous Enoxaparin in Preventing Venous Thromboembolism in Patients Admitted to Intensive Care Unit
by: Masoum Khoshfetrat, et al.
Published: (2020-05-01)

New Oral Anticoagulants: General Features and Review of Pivotal Clinical Trials
by: Sung-Won Jang
Published: (2016-12-01)

A Low Rivaroxaban Plasma Level May Indicate Anticoagulation Undertreatment
by: Simone Lorenzo Romano, et al.
Published: (2018-10-01)

A study on the role of rivaroxaban in management of venous thromboembolism
by: Mohmed Abdalwahab, et al.
Published: (2015-10-01)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
by: Maha Al-Ghafry, et al.
Published: (2022-10-01)

Bacterial Porins and Their Procoagulant Role: Implication in the Pathophysiology of Several Thrombotic Complications during Sepsis
by: Carmine Siniscalchi, et al.
Published: (2024-08-01)

Intracranial hemorrhage in patient treated with rivaroxaban
by: Michelle Molina, et al.
Published: (2014-03-01)

Venous thromboembolism in patients with heart failure
by: O. V. Averkov, et al.
Published: (2011-08-01)

Comparing direct oral anticoagulants and vitamin K antagonist use in morbidly obese patients with venous thromboembolism: A single center retrospective cohort study
by: Lia C. Scott, et al.
Published: (2022-05-01)

Combined oral contraceptives and the risk of venous thromboembolism carriers of antithrombin, protein C or S deficiency: Sub-analysis of a prospective cohort study
by: Daniela Tormene, et al.
Published: (2022-11-01)

Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism
by: Juan J. López-Núñez, et al.
Published: (2019-01-01)

Prevention of venous thromboembolism with rivaroxaban and apixaban in orthopedic surgery
by: Antonijević Nebojša, et al.
Published: (2020-01-01)

Venous thrombosis recurrence risk according to warfarin versus direct oral anticoagulants for the secondary prevention of venous thrombosis
by: Neil A. Zakai, et al.
Published: (2021-08-01)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
by: Kochawan Boonyawat, et al.
Published: (2021-02-01)

Safety and efficacy of direct oral anticoagulants in chronic kidney disease: a meta-analysis
by: Daniel Tham, et al.
Published: (2024-10-01)

Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors
by: Yoshihisa Nakano, et al.
Published: (2024-10-01)

Thromboembolism and anticoagulation after fontan surgery
by: Sangeetha Viswanathan
Published: (2016-01-01)

Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study
by: Anthonie W. A. Lensing, et al.
Published: (2018-12-01)

Fatigue after initiating rivaroxaban for venous thromboembolism
by: Tina Margrethe Karlsvik, et al.
Published: (2020-05-01)

Current status of venous thromboembolism development during the perioperative period for colorectal cancer, its prevention with enoxaparin, and monitoring methods
by: Aoki J, et al.
Published: (2019-06-01)

Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
by: Rupert Bauersachs, et al.
Published: (2020-05-01)

Pulmonary thromboembolism in an anticoagulated oncological patient
by: Diana Alegre-González, et al.
Published: (2023-08-01)

Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis [version 1; peer review: 2 approved]
by: Ardyan Wardhana, et al.
Published: (2021-12-01)

Association Between Anticoagulation Outcomes and Venous Thromboembolism History in Chronic Thromboembolic Pulmonary Hypertension
by: Yong-Jian Zhu, et al.
Published: (2021-05-01)

Adherence to rivaroxaban for the treatment of venous thromboembolism–Results from the FIRST registry
by: Victoria Speed, et al.
Published: (2021-12-01)

Case report: Successful thromboprophylaxis with enoxaparin in a pregnant woman with internal jugular vein agenesis
by: Pierpaolo Di Micco, et al.
Published: (2022-11-01)

Retrospective Evaluation of Intravenous Enoxaparin Administration in Feline Arterial Thromboembolism
by: Athanasia Mitropoulou, et al.
Published: (2022-08-01)

Gender Differences in Atrial Fibrillation: From the Thromboembolic Risk to the Anticoagulant Treatment Response
by: Anna Rago, et al.
Published: (2023-01-01)

Platelet Count and Bleeding in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism: Lesson from the RIETE Registry
by: Di Micco P, et al.
Published: (2020-01-01)

Rivaroxaban in acute venous thromboembolism: UK prescribing experience
by: Victoria Speed, et al.
Published: (2021-10-01)

Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J’xactly study
by: Shohei Migita, et al.
Published: (2023-08-01)

Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: A meta-analysis
by: Zhuang Liu, et al.
Published: (2023-04-01)